Collegium Pharmaceutical (NASDAQ:COLL) Hits New 12-Month High – Still a Buy?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shares hit a new 52-week high on Friday . The stock traded as high as $50.00 and last traded at $49.9750, with a volume of 203913 shares trading hands. The stock had previously closed at $49.58.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. HC Wainwright upped their price target on Collegium Pharmaceutical from $44.00 to $46.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Barclays initiated coverage on Collegium Pharmaceutical in a research report on Monday, December 8th. They set an “overweight” rating and a $58.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a report on Tuesday, October 28th. Finally, Zacks Research upgraded Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 21st. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Collegium Pharmaceutical has an average rating of “Buy” and a consensus price target of $47.00.

Collegium Pharmaceutical Stock Performance

The company has a market capitalization of $1.58 billion, a PE ratio of 31.05 and a beta of 0.61. The firm has a 50-day moving average of $43.61 and a two-hundred day moving average of $37.16. The company has a quick ratio of 1.27, a current ratio of 1.36 and a debt-to-equity ratio of 2.71.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 EPS for the quarter. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. The business had revenue of $135.55 million for the quarter. Research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Insiders Place Their Bets

In other news, Director Rita J. Balice-Gordon sold 3,650 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $47.03, for a total transaction of $171,659.50. Following the completion of the transaction, the director directly owned 52,629 shares of the company’s stock, valued at $2,475,141.87. This represents a 6.49% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Colleen Tupper sold 30,000 shares of the stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $40.53, for a total transaction of $1,215,900.00. Following the transaction, the chief financial officer directly owned 126,667 shares in the company, valued at approximately $5,133,813.51. The trade was a 19.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 51,250 shares of company stock worth $2,235,352. Company insiders own 2.51% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Federated Hermes Inc. increased its stake in shares of Collegium Pharmaceutical by 67.0% in the 3rd quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 350 shares during the last quarter. CWM LLC grew its holdings in shares of Collegium Pharmaceutical by 453.9% in the second quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 1,153 shares during the period. Hantz Financial Services Inc. increased its position in Collegium Pharmaceutical by 137.7% during the third quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock worth $60,000 after purchasing an additional 993 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in Collegium Pharmaceutical by 744.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock worth $73,000 after purchasing an additional 2,190 shares during the last quarter. Finally, GAMMA Investing LLC raised its stake in Collegium Pharmaceutical by 368.9% during the second quarter. GAMMA Investing LLC now owns 2,757 shares of the specialty pharmaceutical company’s stock worth $82,000 after purchasing an additional 2,169 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.